Loading
A phase 3 trial of Guardant Reveal in Breast cancer, run by SWOG Cancer Research Network, not yet recruiting.
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing is a phase 3 interventional study registered as NCT07802626 by SWOG Cancer Research Network, with 1084 participants planned, started 2026-10-30 and due to reach its primary completion in 2034-10-30. Interventions recorded: NSAI + CDK4/6i, NSAI + CDK4/6i + Capivasertib, Fulvestrant + CDK4/6i + Capivasertib, NSAI + CDK4/6i, Guardant Reveal. Conditions recorded: HR Positive/HER-2 Negative Breast Cancer.
Linked to the drug Guardant Reveal because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/